Republic Technologies Inc. — Capital/Financing Update 2025

Jun 30, 2025

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Beyond Medical Technologies Inc. (the “Company”)
1111 West Hastings Street, 15th Floor
Vancouver, BC V6E 2J3

Item 2. Date of Material Change

The date of the material change is June 23, 2025.

Item 3. News Release

A news release with respect to the material change was disseminated through Newsfile Corp. on June 23, 2025.

Item 4. Summary of Material Change

Beyond Medical Technologies Inc. (CSE: DOCT) has closed the second and final tranche of its non-brokered private placement, raising CAD $418,750 through senior secured, non-interest-bearing convertible notes. The notes are convertible at CAD 0.53 per share and carry a 15% premium at maturity if not converted.

Item 5. Full Description of Material Change

Item 5.1 Full Description of Material Change

The material change is described in the press release attached as Schedule “A”.

Item 5.2 Disclosure for Restructuring Transactions

Not applicable

Item 6. Reliance of subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

---

Not applicable.

Item 8. Executive Officer
Daniel Liu
Chief Executive Officer
Telephone: (650) 676-9562

Item 9. Date of Report
June 25, 2025

---

Schedule “A”

Vancouver, British Columbia – Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement, raising gross proceeds of CAD $418,750.

The Company has issued senior secured, non-interest-bearing convertible notes in connection with this second tranche. The notes are convertible into common shares of the Company at the option of the holder at a conversion price of CAD $0.53 per share. The notes have a 12-month term and do not bear interest.

If the notes are not converted during the term, the Company will pay a 15% premium on the outstanding principal at maturity. Additionally, the notes will automatically convert into common shares in the event the 10-day volume-weighted average price (VWAP) of the Company’s common shares exceeds CAD $1.06.

All securities issued under the financing are subject to a statutory hold period in accordance with applicable securities laws.

Use of Proceeds

The net proceeds from the financing will be used for general working capital purposes and to support the Company’s Ethereum-based attestation business. This includes the potential acquisition of additional Ethereum (ETH) to power Beyond Medical’s blockchain attestation platform, which is used for securing medical records, compliance documentation, and other verifiable healthcare data through smart contracts and decentralized infrastructure.

Continued Marketing Engagement

The Company also announces the continuation of its investor relations and marketing engagement with Fairfax Partners Inc., under a renewed agreement totaling CAD $85,000 over the next three months. Fairfax will continue to provide strategic capital markets support, digital media execution, and shareholder communications. Fairfax remains at arm’s length to the Company and, to the best of the Company’s knowledge, does not hold any securities of Beyond Medical Technologies Inc. as of the date of this news release.

About Beyond Medical Technologies Inc.

Beyond Medical Technologies is a technology company leveraging blockchain infrastructure to build secure, verifiable data infrastructure that serves the public good. Its platform supports applications across healthcare, regulatory compliance, supply chain, financial services, and education.